Predictors of 5-Year Mortality in Patients Managed With a Magnetically Levitated Left Ventricular Assist Device.

[1]  N. Reza,et al.  Representation matters: a call for inclusivity and equity in heart failure clinical trials , 2022, European heart journal supplements : journal of the European Society of Cardiology.

[2]  N. Uriel,et al.  Prediction of Survival After Implantation of a Fully Magnetically Levitated Left Ventricular Assist Device. , 2022, JACC. Heart failure.

[3]  N. Uriel,et al.  Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial. , 2022, JAMA.

[4]  A. Nayak,et al.  Hemodynamic Aberrancies in Left Ventricular Assist Device Associated Heart Failure Syndromes. , 2022, Journal of cardiac failure.

[5]  A. Nayak,et al.  Global challenges in left ventricular assist device therapy: a tale across two continents , 2022, European journal of heart failure.

[6]  Snehal R. Patel,et al.  Impact of Race on Clinical Outcomes After Implantation With a Fully Magnetically Levitated Left Ventricular Assist Device , 2021, Circulation. Heart failure.

[7]  M. Hassanein,et al.  Contemporary Left Ventricular Assist Device Outcomes in an Aging Population: An STS INTERMACS Analysis. , 2021, Journal of the American College of Cardiology.

[8]  F. Pagani,et al.  Long-term survival on LVAD support: Device complications and end-organ dysfunction limit long-term success. , 2021, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[9]  J. Cleveland,et al.  Primary results of long‐term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants , 2021, European Journal of Heart Failure.

[10]  N. Desai,et al.  Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure , 2020, PloS one.

[11]  G. Sayer,et al.  Psychosocial Risk and Its Association With Outcomes in Continuous-Flow Left Ventricular Assist Device Patients , 2020, Circulation. Heart failure.

[12]  É. Marijon,et al.  Early Ventricular Arrhythmias After LVAD Implantation Is the Strongest Predictor of 30-Day Post-Operative Mortality. , 2019, JACC. Clinical electrophysiology.

[13]  Tanya Mashiach,et al.  Blood urea nitrogen variation upon admission and at discharge in patients with heart failure , 2019, ESC heart failure.

[14]  M. Walsh,et al.  A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report , 2019, The New England journal of medicine.

[15]  M. Mehra.  The burden of haemocompatibility with left ventricular assist systems: a complex weave. , 2019, European heart journal.

[16]  J. Cleveland,et al.  Comprehensive Analysis of Stroke in the Long-Term Cohort of the MOMENTUM 3 Study: A Randomized Controlled Trial of the HeartMate 3 Versus the HeartMate II Cardiac Pump , 2019, Circulation.

[17]  G. Bhat,et al.  The Influence of Pre-Left Ventricular Assist Device (LVAD) Implantation Glomerular Filtration Rate on Long-Term LVAD Outcomes. , 2017, Heart, lung & circulation.

[18]  G. Ewald,et al.  Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure , 2017, Circulation.

[19]  Gregory A. Ewald,et al.  A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure , 2017, The New England journal of medicine.

[20]  J. Cleveland,et al.  Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[21]  V. Roger,et al.  Frailty and outcomes after implantation of left ventricular assist device as destination therapy. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[22]  Doron Aronson,et al.  Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. , 2004, The American journal of medicine.